| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/07/1999 | EP0906957A2 Lgt polypeptide |
| 04/07/1999 | EP0906956A2 MurD from Streptococcus pneumoniae |
| 04/07/1999 | EP0906955A2 FtsY |
| 04/07/1999 | EP0906752A1 Use of a plant extract of the Rosaceae family |
| 04/07/1999 | EP0906433A1 Protein tyrosine phosphatases of hematopoietic cells |
| 04/07/1999 | EP0906422A1 Human cell death-associated protein |
| 04/07/1999 | EP0906416A1 Molecules comprising an impdh-like binding pocket and encoded data storage medium capable of graphically displaying them |
| 04/07/1999 | EP0906122A2 Activated linkers and methods for making and purifying the same |
| 04/07/1999 | EP0906121A1 Vasoactive effects and free radical generation by beta-amyloid peptides |
| 04/07/1999 | EP0906107A1 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs |
| 04/07/1999 | EP0906105A1 Improvement of implantation rates after in vitro fertilization |
| 04/07/1999 | EP0906104A1 Method for treating pain |
| 04/07/1999 | EP0906102A1 A process for regulating vagal tone |
| 04/07/1999 | EP0906100A1 Use of 5-ht 1a? receptor antagonists for the treatment of urinary incontinence |
| 04/07/1999 | EP0906099A1 A method of treating cancer |
| 04/07/1999 | EP0906098A1 Virginiamycin mixture |
| 04/07/1999 | EP0906090A1 Method for preventing and treating peripheral neurophathy by administering selegiline |
| 04/07/1999 | EP0906088A1 Liposomal antineoplaston therapies with markedly improved antineoplastic activity |
| 04/07/1999 | CN1213406A Method for inhibiting adenylosuccinate synthetase activity methylthioadenosine phosphorylasse deficient cells |
| 04/07/1999 | CN1213315A Compositions including calcium influx retardant for inhibiting cell growth |
| 04/07/1999 | CN1213314A Improved vision through photodynamic therapy of eye |
| 04/07/1999 | CN1213309A Control of healing process |
| 04/07/1999 | CN1213300A Method for preventing and treating peripheral neurophathy by administering selegiline |
| 04/06/1999 | US5892112 Acylation of amino acids with anhydrides or carboxy groups, amidation with amine and conversion of acid or ester to hydroxamic acid and hydrolysis |
| 04/06/1999 | US5892060 Method for the preparation of (+)-calanolide a and analogues thereof |
| 04/06/1999 | US5892052 Process for making retroviral protease inhibiting compounds |
| 04/06/1999 | US5892014 DNA encoding a protease-activated receptor 3 |
| 04/06/1999 | US5892012 Rab Proteins |
| 04/06/1999 | US5891925 Diagnostic method for assessing the serum cholesterol response to low diets |
| 04/06/1999 | US5891923 Cognition activators |
| 04/06/1999 | US5891885 Method for treating migraine |
| 04/06/1999 | US5891873 Particularly alzheimer's disease. examples include aminoguanidines and amphotericin b. |
| 04/06/1999 | US5891864 Composition comprising acridine derivative and guanosine derivative |
| 04/06/1999 | US5891856 Nonmutating cells by treatment with metabolites and aminoalkylphosphorothioate |
| 04/06/1999 | US5891674 The use of these sequences in the diagnosis, prevention, and treatment of cancer, inflammation, and disorders associated with insulin response. |
| 04/06/1999 | US5891670 Tetracycline resistance protein |
| 04/06/1999 | US5891641 Assay for disease related conformation of a protein |
| 04/06/1999 | US5891472 Topical treatment for administering nitric oxide in lipid based carriers |
| 04/06/1999 | US5891459 Arginine, lysine and salts with nutrients for nitric oxide intermediates |
| 04/06/1999 | CA2135070C Use of guanylate cyclase inhibitors in the treatment of shock |
| 04/06/1999 | CA2061824C Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| 04/01/1999 | WO1999015699A1 Translational frameshift based drug screening assay |
| 04/01/1999 | WO1999015656A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 04/01/1999 | WO1999015653A2 Tie ligand homologues |
| 04/01/1999 | WO1999015635A1 Human ste20-like stress activated serine/threonine kinase |
| 04/01/1999 | WO1999015553A2 Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use |
| 04/01/1999 | WO1999015203A1 Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms |
| 04/01/1999 | WO1999015200A1 MEDICINAL COMPOSITION CONTAINING gp34 BINDING INHIBITOR AS THE ACTIVE INGREDIENT |
| 04/01/1999 | WO1999015196A1 Pharmaceutical substance containing various vitamin k-dependent factors |
| 04/01/1999 | WO1999015189A1 Metal compounds, mixed or sulphated, as phosphate binders |
| 04/01/1999 | WO1999015184A1 New method of treatment |
| 04/01/1999 | WO1999015183A1 PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES |
| 04/01/1999 | WO1999015176A1 Treatment of oppositional defiant disorder |
| 04/01/1999 | WO1999015171A1 Nicotine compositions and methods of formulation thereof |
| 04/01/1999 | WO1999015167A2 Use of citrus limonoids and flavonoids as well as tocotrienols for the treatment of cancer |
| 04/01/1999 | WO1999015166A1 Parasiticidal formulations |
| 04/01/1999 | WO1999015165A1 Topical non-steroidal anti-inflammatory drug composition |
| 04/01/1999 | WO1999015163A1 Treatment of conduct disorder |
| 04/01/1999 | WO1999015162A2 Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid a |
| 04/01/1999 | WO1999015159A2 Methods for increasing apoe levels for the treatment of neurodegenerative disease |
| 04/01/1999 | WO1999015154A1 Methods for fabricating polymer-based controlled release preparations |
| 04/01/1999 | WO1999015153A1 Small particle liposome aerosols for delivery of anti-cancer drugs |
| 04/01/1999 | WO1999002545A3 Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 04/01/1999 | WO1999002133A3 Topical application of a combination of benzoyl peroxide and a second active ingredient |
| 04/01/1999 | WO1999001117A3 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins |
| 04/01/1999 | WO1998056812A3 Estrogen receptor crystals and ligands |
| 04/01/1999 | WO1998056370A3 Therapeutic nanospheres |
| 04/01/1999 | WO1998055615A9 Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
| 04/01/1999 | WO1998053856A9 Methods for the detection, treatment, and prevention of neurodegeneration |
| 04/01/1999 | WO1998052898A9 Pharmaceutical agents for the treatment of cerebral amyloidosis |
| 04/01/1999 | WO1998052616A3 Nonsteroidal antirheumatic agents or thrombocyte-agglutination inhibitors to improve representation of vessels, lymph nodes and bone marrow with pharmaceutical preparations containing particles, vesicles of polymers |
| 04/01/1999 | WO1998051321A9 Tissue factor for influencing blood vessel formation |
| 04/01/1999 | WO1998048785A3 Allelic polygene diagnosis of reward deficiency syndrome and treatment |
| 04/01/1999 | WO1998024482A3 Use of endothelin conjugates in therapy, new endothelin conjugates, substances containing them, and processes for producing them |
| 04/01/1999 | DE19743143A1 Pharmazeutische Kombinationspräparate Pharmaceutical combination preparations |
| 04/01/1999 | DE19743142A1 Pharmazeutische Kombinationspräparate Pharmaceutical combination preparations |
| 04/01/1999 | DE19743140A1 Combination of endothelin antagonist and vasodilator |
| 04/01/1999 | DE19742717A1 Synergistic combination of endothelin antagonist and renin-angiotensin system inhibitor |
| 04/01/1999 | CA2305350A1 Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof |
| 04/01/1999 | CA2304622A1 Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-?b via the ubiquitin proteasome pathway to treat inflammatory and autoimmunediseases |
| 04/01/1999 | CA2304505A1 Methods for increasing apoe levels for the treatment of neurodegenerative disease |
| 04/01/1999 | CA2304396A1 A pharmaceutical preparation comprising vitamin k-dependent single factors |
| 04/01/1999 | CA2304283A1 Parasiticidal formulations |
| 04/01/1999 | CA2304202A1 Use of citrus limonoids and flavonoids as well as tocotrienols for the treatment of cancer |
| 04/01/1999 | CA2304191A1 Topical non-steroidal anti-inflammatory drug composition |
| 04/01/1999 | CA2304162A1 Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms |
| 04/01/1999 | CA2304129A1 Tie ligand homologues |
| 04/01/1999 | CA2304115A1 Treatment of oppositional defiant disorder |
| 04/01/1999 | CA2304042A1 Nicotine compositions and methods of formulation thereof |
| 04/01/1999 | CA2303147A1 Small particle liposome aerosols for delivery of anti-cancer drugs |
| 04/01/1999 | CA2302936A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 04/01/1999 | CA2299320A1 New method of treatment |
| 04/01/1999 | CA2272605A1 Pharmaceutical composition containing gp34 binding-inhibitory agent as effective ingredient |
| 04/01/1999 | CA2246004A1 A kringle-related clone, hthbz47 |
| 03/31/1999 | EP0905250A1 The Chlamydia trachomatis Glutamyl-tRNAGln amidotransferase subunit ratA |
| 03/31/1999 | EP0905249A2 Alcohol dehydrogenase |
| 03/31/1999 | EP0905248A1 Staphylococcus aureus MurE protein and nucleic acids encoding it |
| 03/31/1999 | EP0905247A2 MurF polynucleotides and polypeptides from Staphylococcus |
| 03/31/1999 | EP0905245A1 Staphylococcal polypeptides Spo0J1 |
| 03/31/1999 | EP0905243A2 Polynucleotides from Staphylococcus aureus expressed in infected tissue |